Competing interests
ONCOLOGY
I.M.C. reports institutional research grants from AstraZeneca, Roche, Bristol Myers Squibb, Celgene, Genis, and Varian Medical Systems; advisory board fees from Amgen and AstraZeneca; and travel and accommodation expenses from Roche, Bristol Myers Squibb, Celgene, and Bayer. M.L. received an unrestricted research grant from Scandion Oncology A/S, Denmark. All other authors reported no competing interests.